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Abstract
Background Delayed cerebral vasospasm after aneurysmal
subarachnoid hemorrhage (SAH) is a major cause of high
morbidity and mortality. The reduced availability of nitric
oxide (NO) in blood and cerebrospinal fluid (CSF) is well
established as a key mechanism of vasospasm. Systemic
administration of glyceryl trinitrate (GTN), an NO donor
also known as nitroglycerin, has failed to be established in
clinical settings to prevent vasospasm because of its
adverse effects, particularly hypotension. The purpose of
this study was to analyze the effect of intrathecally
administered GTN on vasospasm after experimental SAH
in the rabbit basilar artery.
Methods A single-hemorrhage model of SAH in rabbits
was used to induce vasospasm. GTN (0.5 mg/ml) or saline
was infused via a subcutaneous implanted osmotic pump
with continuous drug release into the cerebellomedullary
cistern over 5 days. The degree of vasospasm in the basilar
artery was recorded with angiography on day 5 after SAH
and was compared to baseline angiography on day 0.
Findings Significant reduction of basilar artery diameter
was observed in the SAH group with saline infusion
compared to sham-operated animals. Intrathecally adminis-
tered GTN had no effect on the vessel diameter in sham-
operated animals, whereas it significantly prevented vaso-
spasm in the SAH group. Intrathecal GTN infusion did not
affect arterial blood pressure.
Conclusions Prophylactic, continuous intrathecal adminis-
tration of GTN prevents vasospasm of the basilar artery in
the rabbit SAH model. No toxic effects could be demon-
strated in this study. The clinical safety and feasibility of
this strategy need to be further investigated.
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Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) occurs in
~15/100,000 persons each year. Delayed ischemic neuro-
logical deficit (DIND) develops within 14 days after aSAH
and remains the major cause of unfavorable outcome in 25–
30% of these patients [8, 9]. The underlying causes of
DIND are multifactorial. Nevertheless, arterial narrowing in
the time course of DIND, also known as delayed cerebral
vasospasm, is a major cause of territorial and/or lacunar
brain infarctions [7].
Vasospasm itself underlies a number of different patho-
physiological factors. A key factor is the reduced intraar-
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terial [16] and cerebrospinal fluid (CSF) [20, 35] concen-
trations of nitric oxide (NO) as an endothelial-derived
relaxing factor (EDRF) after SAH. The pathophysiological
mechanisms are mainly the dysfunction of the NO-
producing enzyme nitric oxide synthase (NOS) and
scavenging of NO due to the presence of deoxyhemoglobin
and its high affinity for NO [6]. Based on these facts,
classic NO donors [sodium nitroprusside and glyceryl
trinitrate (GTN)] have been administered in several exper-
imental settings since the early 1970s [21] in order to
enhance NO concentrations and dilate spastic vessels.
Sodium nitroprusside is the most frequently used of
these substances, and has been administered intrathecally in
several human studies in order to bypass the side effects of
systemic administration, such as hemodynamic hypotension
and development of tolerance [24, 31]. Despite positive
effects on vessel diameter, its routine clinical application
has been limited by side effects, such as nausea and
vomiting, cardiac arrhythmia, and intracranial hypertension.
GTN has been shown to dilate cerebral vessels after
experimental SAH and in the clinical setting by intrave-
nous, intraarterial or transdermal administration. In three
clinical studies, side effects similar to those seen with
sodium nitroprusside developed after systemic administra-
tion of the drug (intravenous and transdermal) and therefore
limited its use for treatment of vasospasm [13, 26, 29].
Intrathecal administration of GTN has not been tested in
clinical studies as of yet.
In a previous study we used intrathecal GTN infusion as
a control to the nimodipine infusion group [14]. Despite
promising results, this study has been criticized because of
remarkable vasospasm in the control group and lack of
sham-operated control. More recently, Pluta et al. published
a study in primates questioning the effect of intrathecally
administered drugs [19]. Consequently, the present study
was specifically designed to elucidate the effects of
continuous intrathecal GTN on prevention of SAH-
induced cerebral vasospasm in an optimized study protocol
compared to a sham-operated control.
Methods
The study was performed in accordance with the National
Institutes of Health guidelines for the care and use of
experimental animals, and with the approval of the Animal
Care Committee of the Canton of Bern, Switzerland
(approval no. 63/03).
Study design
Forty-six adult male New Zealand White rabbits weighing
3–5 kg were randomly assigned to four experimental
groups (6 animals excluded): group 1: sham operation with
saline infusion (n=10); group 2: sham operation with
continuous GTN infusion (n=10); group 3: SAH with
saline infusion (n=10); group 4: SAH with continuous
GTN infusion (n=10). All surgical procedures were
performed under sterile conditions.
Anesthesia, monitoring, and euthanasia
Induction of general anesthesia was performed by
intramuscular administration of ketamine (30 mg/kg)
(Ketalar® 50 mg/ml, Pfizer AG, Zurich, Switzerland)
and xylazine (6 mg/kg) (Xylapan® 20 mg/mL, Vétoqui-
nol AG, Bern, Switzerland). During surgery, pain
evaluation was performed periodically by toe-pinch.
Postoperative pain relief was managed by subcutaneous
administration of buprenorphine (0.1–0.2 mg/kg; Temgesic®
0.3 mg/ml, Essex Chemie AG, Lucerne, Switzerland) for
up to 36 h after SAH. The animals were killed on day 5
post-SAH induction by intraarterial bolus injection of
sodium thiopental (40 mg/kg) (Pentothal®, Ospedalia
AG, Hünenberg, Switzerland), the same anesthetic used
for angiography.
Heart rate and blood pressure were monitored
throughout the digital subtraction angiography (DSA)
on day 0 and day 5 after experimental SAH. Intravascu-
lar pressures and heart rate were measured with a
Camino® Multi-Parameter Monitor (Integra™, Plains-
boro, NJ). On the same days, arterial blood gas status
was analyzed from collected arterial blood samples in
order to monitor oxygenation parameters (ABL 725,
Radiometer, Copenhagen, Denmark). The animals under-
went daily clinical observation.
Angiography
After induction of general anesthesia by intramuscular
administration of ketamine (30 mg/kg) and xylazine
(6 mg/kg), DSA was performed on day 0 and day 5, as
reported previously.[15]. In brief, the rabbit’s left (day 0) or
right (day 5) subclavian artery was microsurgically exposed
and cannulated using a 5.5-French pediatric three-lumen
central venous catheter (Arrow Int. Inc., Reading, PA).
Subsequently, images of the vertebro-basilar system were
obtained by rapid sequential DSA using intraarterial bolus
injections of non-ionic iopamidol (0.6 ml/kg; Iopamiro®
300 mg/ml, Bracco, Milan, Italy) as contrast agent. The
average diameter of the basilar artery (BA) was digitally
calculated in μm using the automatic measurement tool of
the ImagePro Discovery® analysis software (Media Cyber-
netics, Bethesda, MD). Measurements were performed by
three blinded investigators, and mean values were used for
statistical analysis.
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Cerebral vasospasm model
Following baseline DSA on day 0, the atlanto-occipital
membrane was microscopically exposed, and a 25-gauge
needle was inserted into the cerebromedullary cistern. After
relief of 1.0 mL of CSF, an equal amount of nonheparinized
autologous arterial blood (saline in sham group) was
injected into the cistern under microscopic view [3]. The
rabbits were kept positioned at a 65° angle, head-down, for
10 min in order to allow blood dissemination throughout
the subarachnoidal space.
Implantation of miniosmotic pump
A miniosmotic pump (0.5 μl/h, model 1007D, Alzet
Osmotic Pumps, Durect, Cupertino, CA) containing either
0.5 mg/ml of GTN solution (pH 7.35; Perlinganit, Schwarz
Pharma, Münchenstein, Switzerland) or sodium chloride
(NaCl) was implanted subcutaneously. This pump model
ensures a drug release over 7 days. The dose of GTN was
derived from studies with sodium nitroprusside administra-
tion in humans in which up to 8 mg/24 h was used for
prophylaxis against vasospasm [30, 31]. Pumps, associated
tubing, and drugs were protected from light at all times. A
silicone catheter (STH-C040, Connectors Verbindungstech-
nik, Tagelswangen, Switzerland) was connected to the pump
and inserted under microscopic view at least 1 mm through the
atlanto-occipital membrane into the subarachnoid space. The
tube insertion site was sealed by a muscle patch and fixed by
several stitches. The midline spinal muscle incision was
closed in two layers. Finally, the wounds were superficially
irrigated with neomycin sulfate (Research Organics, Cleve-
land, OH) for infection prophylaxis.
Statistical methods
Values were expressed as a mean in each group±SEM (n=
number of animals). Statistical significance between two
means and multiple means was determined by parametric
one-way ANOVA and Bonferroni’s multiple comparisons
post-testing, respectively. Statistical significance was con-
sidered if the P value was less than 0.05 (p<0.05) in the
context of 95% confidence intervals of the differences
examined (95% CI of difference).
Results
Physiological data
Mean arterial blood pressure (mean 73±12.64 mmHg) and
heart rate (mean 165.5±5.9) were not significantly different
among the study groups (p>0.05). Blood gas analysis
showed no significant difference for pCO2 (mean 43.79±
5.50 mmHg, p>0.05), pO2 (mean 77.8±10.4 mmHg, p>
0.05), or pH (mean 7.37±0.1, p>0.05) (Table 1).
Morbidity, mortality, and neurological status
Five rabbits had to be euthanized before completion of the
studies because of poor clinical conditions and were
excluded from analysis. Three of them had permanent
paralysis of the lower extremities after SAH induction,
while two other animals had loss of appetite and deterio-
rated in general condition. Clinical daily follow-up of the
remaining animals was uneventful up to day 5. Gross
pathological evaluation revealed no signs of infection. All
of the implanted pump devices were precisely placed 1–
2 mm beneath the atlanto-occipital membrane.
Angiographic measurements
A total of 80 angiograms of the basilar artery were
analyzed. There were no significant differences in the
intra- and interobserver analyses (p>0.05). Baseline vessel
diameter on day 0 did not significantly differ among the six
experimental groups. Basilar artery diameter changes in
sham-operated animals were not significantly different
between saline (4.57±3.6%) and GTN (8.8±5.1%) groups
(p>0.05). In the SAH group with saline infusion, basilar
artery diameter was significantly reduced (16.2±2.8%) on
day 5 compared to baseline values (p<0.05). The BA
Table 1 Physiological data of the animals during final angiogram
Sham/NaCl Sham/GTN SAH/NaCl SAH/GTN
MABP (mmHg) 72.8±4.3 73.5±2.1 74.2±2.4 70.9±2.6
Heart Rate 159±6 163±4.8 168±5.4 172±7.5
pO2 (mmHg) 79.4±14.1 80.5±14.4 76.1±7.1 75.3±5.9
pCO2 (mmHg) 44.6±1.1 43.8±2.3 41.5±3.5 44.7±2.2
pH 7.4±0.01 7.36±0.02 7.37±0.02 7.36±0.02
There is no significant difference for each parameter between the groups. NaCl: sodium chloride, GTN: glyceryl trinitrate, SAH: subarachnoid
hemorrhage, MABP: mean arterial blood pressure. Values are mean ± standard error of mean
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diameter after SAH and continuous GTN showed signifi-
cant prevention of the vessel constriction and was reduced
by only 2.29±3.4% (p<0.05; Fig. 1).
Discussion
This study confirms that intrathecal continuous infusion of
GTN prevents delayed cerebral vasospasm of the rabbit
basilar artery after SAH.
Nitric oxide donors have been proven to be effective
for reversal and prevention of vasospasm in experimental
and clinical trials for almost 4 decades [1, 21]. However,
routine clinical application has been limited because of
systemic side effects. Intravenous and transdermal GTN
have been tested in three clinical trials showing dilative
effects on vessel diameter (Table 2) [13, 26, 29]. However,
further clinical evaluation was abandoned because of
systemic side effects. Although several animal studies
have shown a beneficial effect of GTN (Table 3), the effect
of intrathecal GTN administration with the intention of
bypassing these side effects has not been conclusively
investigated. In a previous study with intrathecal nimodi-
pine and GTN, we have shown the feasibility of
intrathecal administration of GTN [14]. The present study
confirms that intrathecal administration of GTN is safe and
prevents vasospasm at lower dosage over 5 days of
infusion in a rabbit model.
The clinical status and the arterial blood pressure at day
5 did not indicate a drop in blood pressure compared to day
0. Since pH and pO2 can alter pCO2 and thus influence
cerebral autoregulation and vessel diameter [4], we exclud-
ed the effect of these parameters by maintaining compara-
ble values in all study groups. However, we did not
measure the concentration of the NO metabolome in CSF
and in blood for correlation studies with clinical data.
Another limitation of the systemic application of GTN as
prescribed for long-term use in angina pectoris treatment is
the development of drug tolerance [10]. Since the vaso-
dilatory effect is present after 5 days of continuous infusion,
we conclude that there is no drug tolerance in this short
period of treatment. Considering that peak vasospasm after
SAH occurs between days 3 and 14, we do not expect
tolerance to develop during short-term treatment in SAH
patients receiving GTN.
Pluta et al. investigated the extent of intrathecal drug
distribution around the middle cerebral artery in the primate
model of SAH and expressed concern about sufficient drug
penetration through the blood clot to the artery [19].
However, the present study, like others with sodium
nitroprusside, has demonstrated that this limitation does
not apply to NO donors since the vasoactive effect remains
unaffected by the presence of the blood clot. The main
Table 2 Clinical studies with nitroglycerin
Author Year Journal Administration
route
Assessment method Results Comments
Tanaka 2001 Acta Neurochirurgica Intravenous Neurological outcome DIND 24% in nitroglycerin group
vs. 60% in Fasudil group alone
25 patients in combination
with Fasudil
Lesley 2003 American Journal
of Neurorad
Transdermal Arteriogram Improvement of CVS signs in all
patients (no outcome data)
5 patients, technical note
Reinert 2004 Neurological Research Transdermal TCD and CT perfusion TCD velocity significantly
decreased in nitroglycerin group
9 patients, 8 controls
None of the human studies tested intrathecal administration of nitroglycerin
TCD: Transcranial Doppler
Fig. 1 Relative changes of basilar artery diameter compared to
baseline angiograms. Glyceryl trinitrate (GTN) has no significant
effect on the basilar artery in sham-operated animals. Subarachnoid
hemorrhage (SAH) induces significant vasospasm in the basilar artery,
while GTN prevents vasospasm (*p<0.05)
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reason for this might be that the viscosity of Evans blue (in
Pluta’s study) [19] is not comparable to the viscosity of
nitric oxide donors, and moreover, once NO is released
from GTN, it has very high tissue permeability and diffuses
freely across membranes.
Another concern with intrathecal administration of drugs
is catheter infections resulting in meningitis and ventricu-
litis. Infection risk might be reduced by implanting
antibiotic-impregnated catheters [28]. Moreover, the intra-
thecal route might become more accessible since studies
with intrathecal rTPA, cisternal washing, and lumbar CSF
drainage may be more applicable in combination with NO
donors and similar drugs that are more feasibly adminis-
tered this way [11].
Intrathecal sodium nitroprusside, a different class of NO
donor, is the only NO donor that has been tested
intrathecally in clinical studies after SAH, and has also
been proven to dilate constricted vessels (Table 4) [1, 12,
17, 18, 23, 24, 30, 31, 33]. However, systemic side effects,
especially cyanide poisoning [25], have limited further use
of this drug. Since GTN has different mechanisms of NO
release than sodium nitroprusside, distinct patterns of
adverse effects are expected. However, this has yet to been
confirmed and evaluated in clinical studies.
Our study confirms the important role of NO in the
pathophysiology of vasospasm, as reported with other
classes of NO donors in experimental settings. Among
them, NONOates represent a distinct class of NO donors
Table 4 Clinical studies with Sodium nitroprusside as an NO donor and intrathecal application
Author Year Journal Results Assessment method Comments
Thomas 1999 Neurosurgery Reversal, all 3 patients with good outcome Arteriogram and TCD 3 patients
Thomas 1999 Stroke Reversal in 6/15 patients Arteriogram and TCD 15 patients
Vajkoczy 2000 Stroke Reversal of CVS CPP, brain O2 saturation Case report
Raabe 2002 JNNP Reversal of CVS Brain O2 saturation Case report
Raabe 2002 Neurosurgery 1 patient with angiographic reversal, no
difference in outcome between treated
and untreated patients
Arteriogram and brain
O2 saturation
13 patients
Kumar 2003 Neurol India Reversal, good outcome in 6/10 Arteriogram and TCD 10 patients
Pathak 2003 Br J Neurosurg Prevention and reversal, good outcome
in 5/8 patients
TCD 8 patients
Pachl 2005 Acta Neurochirurgica Prevention in 13/17 TCD, GCS 16 patients, inhomogeneous
study design
Agrawal 2009 Minim Invas Neurosurg Reversal, good outcome in 7/10 TCD 10 patients
TCD: Transcranial Doppler, CPP: Cerebral perfusion pressure, GCS: Glasgow Coma Scale
Table 3 Experimental studies with nitroglycerin
Author Year Journal Animal type In vivo/ex vivo Administration route Assessment method
Poletti 1972 Surg Forum Dog In vivo Local perivascular In vivo visualization
Kistler 1979 Stroke Dog In vivo Intravenous Arteriogram
Shimizu 1980 Stroke Dog Ex vivo Local perivascular Ex vivo analysis
Frazee 1981 J Neurosurg Primate In vivo Intravenous Arteriogram
VonEssen 1981 Stroke Dog In vivo Intravenous CBF and ICP
Kistler 1982 Arch Neurolo Primate In vivo Intravenous and intraarterial Arteriogram
Liszczak 1983 J Neurosurg Dog In vivo Intravenous Arteriogram
Kanamaru 1989 J Neurosurg Primate In vivo Local perivascular Ex vivo analysis
Nakao 1996 Stroke Primate In vivo Intravenous Arteriogram
Thomas 1997 Neurosurgery Rabbit In vivo Local perivascular In vivo visualization
Ito 2000 J Cardiovasc Pharmacol Rabbit In vivo Transdermal Arteriogram
Tanaka 2001 Neurol Med Chir (Tokyo) Dog Ex vivo Local perivascular Ex vivo analysis
Marbacher 2008 Intensive Care Medicine Rabbit In vivo Intrathecal Arteriogram
TCD: Transcranial Doppler, CBF: Cerebral blood flow, ICP: Intracranial pressure
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that have been tested intrathecally in animal studies using
polymer pellets [2, 22, 32, 34]. Other than one study in
primates [2], all other studies with NONOates have shown
significant vessel dilation. One drawback with NONOates
is that they have been shown to open the blood-brain barrier
at higher doses und thus provoke brain infarction and toxicity
[5]. Other classes of NO donors that have been tested in
experimental settings are S-nitrosothiols and sodium nitrite
[20, 27]. Preliminary results are very promising, but the
therapeutic value has yet to be confirmed.
Despite certain limitations of the single-hemorrhage
rabbit model of SAH, it provides a reliable screening method
to evaluate the therapeutic potential of various drugs. This
applies particularly to the vast array of nitric oxide donors
and the need to investigate doses and administration routes.
This study serves as a proof of concept for development of
new treatment strategies such as intrathecal delivery of NO
donors. It is of utmost importance to consider the
multifactorial course of the disease, and thus to consider
the therapeutic aspects as multidirectional as well. This
includes the neuroprotective effect of nimodipine, opti-
mized clinical management, NO donors, and anti-
inflammatory therapeutics. In this multidirectional treat-
ment approach one goal should be the reduction of
individual drug dosages in order to minimize side effects.
Many patients are referred several days after SAH and
may present with clinical and angiographic signs of
vasospasm. Whether intrathecal GTN can reverse estab-
lished vasospasm in this specific patient group remains
unclear. Thus, addition studies are warranted to address the
effect of intrathecal NO not only for prevention but also for
reversal of vasospasm.
Conclusion
Intrathecal administration of the NO donor GTN attenuates
vasospasm in the rabbit single-hemorrhage SAH model.
Further experimental and clinical evaluation of different
classes of NO donors is necessary in order to ascertain the
best source and administration route of NO and to optimize
its therapeutic potential.
Conflicts of interest None.
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Comment
In the present report, the authors have studied the effects of intrathecal
administration of the NO donor glyceryl trinitrate using a single-
hemorrhage model in the rabbit. GTN is shown to reduce the SAH-
associated vasoconstriction of the basilar artery by approximately 10%
during a 5-day infusion protocol using osmotic mini pumps. The
results are statistically significant but seem to be not too impressive
with respect to clinical relevance, especially in light of the drawbacks
of the single-hemorrhage model in the rabbit. On the other hand, this
study may serve as a proof of concept for further development of
strategies that aim at local delivery of NO donors to the basal
cisterns. We strongly believe that the recent, disappointing results
with the systemic administration of vasoactive drugs in order to
prevent cerebral vasospasm underline the necessity of promoting
alternative routes of drug administration, especially directly to the
affected blood vessels. This can be achieved by using continuous
infusion techniques or the use of slow-release formulations. For the
future, this certainly is the most promising concept for achieving
an optimal vasodilatory effect at the vessels and, at the same time,
avoiding systemic side effects that might counteract the beneficial
effect of the drug.
Peter Vajkoczy
Berlin, Germany
This paper explores the use of nitiric oxide donors in the
intrathecal space for the treatment of subarachnoid hemorrhage. The
topic itself is not new. Intrathecal pumps and intrathecal polymers
delivering nitric oxide agents directly to the subarachnoid space have
been tested in trials over the last several years, mostly with
encouraging reductions in pathological markers of vasospasm. In the
vein of these past studies, the authors have demonstrated that glyceryl
trinitrate, a compound previously abandoned as a systemic therapy for
vasospasm, may have genuine therapeutic value as an intrathecal
agent. They demonstrate that intrathecal delivery of this nitric oxide
donor does not produce the same prohibitive hypotension noted in
systemic administration. While they also demonstrate that basilar
artery diameter reduction was less with the experimental arm, it would
be interesting to know whether delayed administration of this drug
would produce similar results. Few patients, after all, could have
intrathecal administration of a drug immediately with their aneurismal
rupture. The concept is clever and promising, and we hope to learn
more from this group.
Markus J. Bookland
Christopher Loftus
Philadelphia, PA
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